Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
Investor attention is increasingly centered on tividenofusp alfa for Hunter syndrome, with an upcoming FDA action date viewed as a key test of Denali's therapeutic approach. We'll now examine how anticipation around the FDA decision on tividenofusp alfa could influence Denali's investment narrative and risk profile. Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution. What Is Denali Therapeutics' Investment Narrative? To own Denali today, you have to believe its blood–brain barrier platform can convert scientific promise into a durable rare-disease franchise, despite steep losses and no meaningful revenue. The recent Miami conference appearances mainly reinforce that story rather than change it, by putting tividenofusp alfa and the broader Enzyme Transport Vehicle pipeline in front of a high-profile investor audience ahead of the April 5 FDA decision. In the short term, the key catalyst remains t
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $29.00 to $32.00. They now have an "outperform" rating on the stock.MarketBeat
DNLI
Earnings
- 2/26/26 - Beat
DNLI
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 8-K
- 2/26/26 - Form 10-K
- DNLI's page on the SEC website